New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient

Current Opinion in Critical Care

Volumn 11, Issue 5, 2005, Pages 481-486

  Schmidt Ioanas, Malina ^a   De Roux, Andres ^a   Lode, Hartmut H ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Antibiotics; Critically ill; Methicillin resistance; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFTOBIPROLE; CEFTRIAXONE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; ORITAVANCIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTHRALGIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYALGIA; NAUSEA AND VOMITING; NONHUMAN; PNEUMONIA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; THROMBOPHLEBITIS;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS; CRITICAL ILLNESS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCOPEPTIDES; HUMANS; METHICILLIN RESISTANCE; MINOCYCLINE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; VIRGINIAMYCIN;

EID: 26944452422     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000176690.18433.22     Document Type: Review

References (56)

1. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004; 24:111-118.
2. Annual Report EARSS. 2001. http://www.earss.rivm.nl. 2002.
3. Legras A, Malvy D, Quinioux AI, et al. Nosocomial infections: prospective survey of incidence in five French intensive care units. Intensive Care Med 1998; 24:1040-1046.
4. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150:1545-1549.
5. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methiollin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-59.
6. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49:999-1005.
7. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-174. This is an exceptional study that should be compared by the reader with a previous investigation of the same authors [5].
8. Merrer J, Santoli F, et al. 'Colonization pressure' and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000; 21:718-723.
9. Bonten MJ. Infection in the intensive care unit: prevention strategies. Curr Opin Infect Dis 2002; 15:401-405.
10. Rello J, Quintana E, Ausina V, et ai. Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142: 1320-1324.
11. Rello J, Ausina V, Ricart M, et al. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104:1230-1235.
12. Rello J, Ausina V, Castella J, et al. Nosocomial respiratory tract infections in multiple trauma patients. Influence of level of consciousness with implications for therapy. Chest 1992; 102:525-529.
13. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136:834-844.
14. Pujol M, Corbella X, Pena C, et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17:622-628.
15. Grundmann H, Hori S, Winter B, et al. Risk factors for the transmission of methicillin-resistant Staphylococcus aureus in an adult intensive care unit: fitting a model to the data. J Infect Dis 2002; 185:481-488.
16. Cui L, Murakami H, Kuwahara-Arai K, et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44:2276-2285.
17. Walsh TR, Howe RA. The Prevalence and Mechanisms of Vancomycin Resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56:657-675.
18. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb Mortal Wkly Rep 2002; 51:565-567.
19. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-1673.
20. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 35:865-871.
21. Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281-286.
22. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 2004; 17:549-555.
23. Shah PM. The need for new therapeutic agents: what is the pipeline? Clin Microbiol Infect 2005; 11(Suppl 3):36-42.
24. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005; 5:209-218. The author presents a complete review on the mechanisms of action and resistance of gram-positive microorganisms to the newer antibiotics and a brief overview on the factors contributing to resistance development.
25. Rybak MJ, Herhberger E, Moldovan T, et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44:1062-1066.
26. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51:1431-1434.
27. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005; 55: 333-340. An interesting study covering the issue of linezolid pharmacokinetics in critically ill patients and showing that renal adjustment by a dosage of 600 mg every 12 his not required in these patients.
28. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus Vancomycin in the Treatment of Hospitalized Patients with Nosocomial Pneumonia: A Randomized. Double-Blind, Multicenter Study. Clin Infect Dis 2001; 32:402-412.
29. Wunderink RG, Cammarata SK, Oliphant TH, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-992.
30. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs Vancomycin. Analysis of two Double-Blind Studies of Patients with Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest 2003; 124:1789-1797.
31. Kollef MH, Rello J, Cammarata SK, et al. Clinical Cure and Survival in Gram-positive Ventilator-associated Pneumonia. Retrospective Analysis of Two Double-blind Studies Comparing Linezolid with Vancomycin. Intensive Care Med 2004; 30:388-394. Here is an excellent investigation that supports the superiority of linezolid in VAP by MRSA. This study is a retrospective analysis of 544 VAP patients. When only MRSA cases were taken into account, linezolid was associated with significantly higher rates of clinical cure (62.2% versus 21.2. p = 0.001), survival (84.1% versus 61.7%, p = 0.02), and eradication (60.5% versus 22.9%, p = 0.001), compared to vancomycin.
32. Stevens DL, Herr D, Lampins H, et al. and the Linezolid MRSA Study Group: Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. Clin Infect Dis 2002; 34:1481-1490.
33. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53:345-355. The study shows that linezolid is associated with a significantly lower colonization rate by MRSA in comparison to teicoplanin in critically ill patients with gram-positive infection.
34. Shorr AF, Susla GM, Kollef MH. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 2004; 32: 137-143.
35. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21:1010-1013.
36. Nasraway SA, Shorr AF, Kuter DJ, et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37:1609-1616.
37. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004; 53:646-649.
38. Ross JE, Anderegg TR, Sader HS, et al. Trends in linezolid susceptibility patterns in 2002: Reprot from the worldide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn Microbiol Infect Dis 2005; 42:53-58.
39. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346:867-869.
40. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infections due to vancomycin-resistant Enterococcus faecius resistant to linezolid. Lancet 2001; 357:1179.
41. Fagon JY, Patrick H, Haas DW, et al. and the Nosocomial Pneumonia Group: Treatment of Gram-positive Nosocomial Pneumonia. Prospective Randomized Comparison of Quinupristin/Dancomycin. Am J Respir Crit Care Med 2000; 161:753-762.
42. Malbruny B, Canu A, Bozdogan B, et al. Resistance to quinupristin- dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:2200-2207.
43. Critchley IA, Draghi DC, Sahrm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogen cellected in the SECURE study (Europe) during 2000-2001. J Antimiorob Chemother 2003; 51:639-649.
44. Fenton C, Keating GM, Cuuran MP. A comprehensive review of the pharmacology of daptomycin. Drugs 2004; 64:445-455.
45. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.
46. Cercenado E, Cercenado S, Gomez JA, Bouza E. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterocovvi and staphylococci with diminished susceptibility to glycopeptide. J Antimicrob Chemother 2003; 52:138-139.
47. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704-714.
48. Murray J, Wilson S, Klein S, et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalised patients. A phase 2 clinical trial [abstract]. 43rd International Conference Antimicrobial Agents Chemotherapy 2003. Chicago, IL, USA. Abstract L739 2005.
49. Kosowska K, Hoellman DB, Lin G, et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:1932-1942.
50. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:884-888.
51. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 2004; 48:3043-3050.
52. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601-1607.
53. Giamarellou H, O'Riordan W, Harris H, et al. Phase 3 trial comparing 3-7 days of orintavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin tructure infections(cSSSI) [abstract]. 43rd International Conference Antimicrobial Agents Chemotherapy 2003. Chicago, IL, USA. Abstract L-739 2003.
54. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48:137-143.
55. Lefort A, Pavie J, Garry L, et al. Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin. Antimicrob Agents Chemother 2004; 48:1061-1064.
56. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374-380. This phase 2 trial reports promising results of the novel drug dalbavancin in a single dosage in comparison to vancomycin in patients who have a catheter-related infection by gram-positive bacteria.